RU2015108678A - Составы ангиотензина для перорального применения - Google Patents
Составы ангиотензина для перорального применения Download PDFInfo
- Publication number
- RU2015108678A RU2015108678A RU2015108678A RU2015108678A RU2015108678A RU 2015108678 A RU2015108678 A RU 2015108678A RU 2015108678 A RU2015108678 A RU 2015108678A RU 2015108678 A RU2015108678 A RU 2015108678A RU 2015108678 A RU2015108678 A RU 2015108678A
- Authority
- RU
- Russia
- Prior art keywords
- dosage form
- solid dosage
- form according
- angiotensin
- amino acids
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000007909 solid dosage form Substances 0.000 claims abstract 64
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract 30
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 claims abstract 23
- FUJLYHJROOYKRA-QGZVFWFLSA-N O-lauroyl-L-carnitine Chemical group CCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FUJLYHJROOYKRA-QGZVFWFLSA-N 0.000 claims abstract 8
- 230000001681 protective effect Effects 0.000 claims abstract 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract 6
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical group O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 claims abstract 4
- 238000010521 absorption reaction Methods 0.000 claims abstract 4
- 239000003623 enhancer Substances 0.000 claims abstract 4
- 239000002775 capsule Substances 0.000 claims abstract 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000011975 tartaric acid Substances 0.000 claims abstract 2
- 235000002906 tartaric acid Nutrition 0.000 claims abstract 2
- 150000001413 amino acids Chemical group 0.000 claims 18
- 108010021281 angiotensin I (1-7) Proteins 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 108010069514 Cyclic Peptides Proteins 0.000 claims 5
- 102000001189 Cyclic Peptides Human genes 0.000 claims 5
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 238000007385 chemical modification Methods 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000000717 retained effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- -1 PROSOLV® Substances 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 239000001744 Sodium fumarate Substances 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 230000006320 pegylation Effects 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 229940005573 sodium fumarate Drugs 0.000 claims 1
- 235000019294 sodium fumarate Nutrition 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 abstract 2
- 239000006186 oral dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261701972P | 2012-09-17 | 2012-09-17 | |
| US61/701,972 | 2012-09-17 | ||
| PCT/US2013/060139 WO2014043693A1 (en) | 2012-09-17 | 2013-09-17 | Oral formulations of angiotensin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015108678A true RU2015108678A (ru) | 2016-11-10 |
Family
ID=50278763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015108678A RU2015108678A (ru) | 2012-09-17 | 2013-09-17 | Составы ангиотензина для перорального применения |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150246093A1 (enExample) |
| EP (1) | EP2895154A4 (enExample) |
| JP (1) | JP2015529684A (enExample) |
| KR (1) | KR20150065736A (enExample) |
| CN (1) | CN104853749A (enExample) |
| AU (1) | AU2013315004A1 (enExample) |
| BR (1) | BR112015005738A2 (enExample) |
| CA (1) | CA2884792A1 (enExample) |
| HK (1) | HK1213785A1 (enExample) |
| IN (1) | IN2015DN03132A (enExample) |
| MX (1) | MX2015003407A (enExample) |
| RU (1) | RU2015108678A (enExample) |
| WO (1) | WO2014043693A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2973099C (en) * | 2015-01-12 | 2021-09-14 | Enteris Biopharma, Inc. | Solid oral dosage forms |
| WO2017049140A2 (en) * | 2015-09-18 | 2017-03-23 | Wake Forest University Health Sciences | Angiotensin (1-7) analogs and methods relating thereto |
| US20250302912A1 (en) * | 2021-10-13 | 2025-10-02 | Chugai Seiyaku Kabushiki Kaisha | Composition including peptide compound and surfactant |
| WO2023214509A1 (ja) * | 2022-05-02 | 2023-11-09 | 中外製薬株式会社 | 界面活性剤と併用するためのペプチド化合物を含む組成物 |
| TW202428307A (zh) * | 2022-10-12 | 2024-07-16 | 日商中外製藥股份有限公司 | 包含胜肽、界面活性劑及聚合物的組成物 |
| WO2024219446A1 (ja) * | 2023-04-19 | 2024-10-24 | 中外製薬株式会社 | 環状ペプチド化合物及び界面活性剤を含む組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| AU2003217783A1 (en) * | 2002-02-27 | 2003-09-09 | Wake Forest University | Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth |
| US8093207B2 (en) * | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
| WO2008130217A1 (en) * | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
| US20080199434A1 (en) * | 2006-11-13 | 2008-08-21 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for the treatment of cardiovascular conditions |
| US8377863B2 (en) * | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| BRPI0800585B8 (pt) * | 2008-02-13 | 2021-05-25 | Univ Minas Gerais | composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) |
| ES2393455T3 (es) * | 2008-09-12 | 2012-12-21 | Charité-Universitátsmedizin Berlin (Charité) | Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas |
| WO2010118232A1 (en) * | 2009-04-09 | 2010-10-14 | Elan Pharma International Limited | Controlled-release clozapine compositions |
| WO2012106427A2 (en) * | 2011-02-02 | 2012-08-09 | University Of Southern California | Methods for treating diabetic foot ulcers |
-
2013
- 2013-09-17 CA CA2884792A patent/CA2884792A1/en not_active Abandoned
- 2013-09-17 JP JP2015532144A patent/JP2015529684A/ja active Pending
- 2013-09-17 WO PCT/US2013/060139 patent/WO2014043693A1/en not_active Ceased
- 2013-09-17 HK HK16101801.9A patent/HK1213785A1/zh unknown
- 2013-09-17 RU RU2015108678A patent/RU2015108678A/ru not_active Application Discontinuation
- 2013-09-17 BR BR112015005738A patent/BR112015005738A2/pt not_active IP Right Cessation
- 2013-09-17 EP EP13836364.3A patent/EP2895154A4/en not_active Withdrawn
- 2013-09-17 IN IN3132DEN2015 patent/IN2015DN03132A/en unknown
- 2013-09-17 KR KR1020157009817A patent/KR20150065736A/ko not_active Withdrawn
- 2013-09-17 AU AU2013315004A patent/AU2013315004A1/en not_active Abandoned
- 2013-09-17 MX MX2015003407A patent/MX2015003407A/es unknown
- 2013-09-17 US US14/428,746 patent/US20150246093A1/en not_active Abandoned
- 2013-09-17 CN CN201380054293.5A patent/CN104853749A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2895154A1 (en) | 2015-07-22 |
| EP2895154A4 (en) | 2016-04-20 |
| MX2015003407A (es) | 2015-10-14 |
| BR112015005738A2 (pt) | 2017-08-08 |
| HK1213785A1 (zh) | 2016-07-15 |
| CN104853749A (zh) | 2015-08-19 |
| AU2013315004A1 (en) | 2015-04-02 |
| KR20150065736A (ko) | 2015-06-15 |
| JP2015529684A (ja) | 2015-10-08 |
| US20150246093A1 (en) | 2015-09-03 |
| CA2884792A1 (en) | 2014-03-20 |
| IN2015DN03132A (enExample) | 2015-10-02 |
| WO2014043693A1 (en) | 2014-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7275207B2 (ja) | 骨粗鬆症の治療 | |
| ES2622468T3 (es) | Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis | |
| CA2726913C (en) | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | |
| ATE254630T1 (de) | Cyclosporine | |
| RU2009111391A (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| JP2004521123A5 (enExample) | ||
| US20250302912A1 (en) | Composition including peptide compound and surfactant | |
| MX2024005883A (es) | Compuesto para el secuestro de anticuerpos no deseables en un paciente. | |
| MX337756B (es) | Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo. | |
| JP2007518724A5 (enExample) | ||
| CA2529604A1 (en) | Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form | |
| FI3998067T3 (fi) | Koostumukset ja menetelmät homokystinurian hoitoon | |
| JOP20250048A1 (ar) | تركيبات للإعطاء عن طريق الفم | |
| MX2023001572A (es) | Formas farmaceuticas sólidas de palbociclib. | |
| US20250186542A1 (en) | Composition containing peptide compound for use with surfactant | |
| ES2547379T3 (es) | Utilización de calcitonina para el tratamiento de la AR | |
| KR20150065736A (ko) | 안지오텐신의 경구 제형 | |
| AR020101A1 (es) | Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado. | |
| US10738084B2 (en) | Macrocycles | |
| MX2011004176A (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo. | |
| EP3054969A2 (en) | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions | |
| JP2015514771A5 (enExample) | ||
| JP2025505861A (ja) | 酸中和ポリマーを含む、副甲状腺ホルモンの経口投与用の製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20160919 |